Sökning: "Sibling donor"
Visar resultat 1 - 5 av 17 avhandlingar innehållade orden Sibling donor.
1. Allogeneic stem cell transplantation : patients’ and sibling donors’ perspectives
Sammanfattning : Allogeneic haematopoietic stem cell transplantation (hereafter HSCT) is an established treatment which offers a potential cure for a variety of diseases, mainly haematological malignancies. However, the treatment is also associated with significant risks of acute complications and late side effects, including mortality. LÄS MER
2. HLA and KIR gene polymorphism in hematopoietic stem cell transplantation
Sammanfattning : The major histocompatibility complex (MHC) in humans known as the Human Leukocyte Antigens (HLA) is localised to the short arm of chromosome six. The HLA class 1 antigens, HLA-A, -B and -C are highly polymorphic glycoproteins expressed on the cell surface of most nucleated cells in the body. LÄS MER
3. Outcome after allogeneic stem cell transplantation with special reference to non-malignant disorders, chimerism and graft cell composition
Sammanfattning : The outcome for patients undergoing allogeneic stem cell transplantation (HSCT), a treatment for several severe malignant and non-malignant disorders with hematopoietic origin, is a balancing act between beneficiary effects and risk factors. Treatment success is still limited by excessive immune response, such as graft-versus-host–disease (GVHD) and graft failure (GF), or the lack thereof as in malignancy relapse or severe infections. LÄS MER
4. Allogeneic stem cell transplantation in children : identification and prevention of complications : adoptive transfer of EBV-immunity
Sammanfattning : Allogeneic stem cell transplantation (SCT) can cure leukaemia, aplastic anaemia, and some inborn errors of metabolism and immunodeficiencies in children. As only 113 of patients who need SCT have an HLA-identical sibling, the use of alternative donors has increased, to over 50% of all paediatric SCTs at our centre. LÄS MER
5. Antitumor effect in allogeneic hematopoietic stem cell transplantation in patients with solid cancer
Sammanfattning : Allogeneic hematopoietic stem cell transplantation (HSCT) has been presented as a promising immunotherapy not only against hematological malignancies but also against solid tumors. Different solid tumors such as renal cell, breast, colon, prostate and advanced primary liver cancer have been treated with HSCT at our center. LÄS MER